Clinical trials: Aml
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer
RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors find better ways to treat the cancer.
- Trial name
- NCT00918658
- Testing
- biologic sample preservation procedure, immunologic technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of Palbociclib in MLL-rearranged Acute Leukemias
Diagnosis: Acute myeloid leukemia; Acute lymphoblastic leukemia Age ≥ 18 years, no upper age limit Study drug: Palbociclib Phase Ib/IIa, open-label Phase Ib: Based on previous experience with 125 mg palbociclib once daily for 21…
- Trial name
- NCT02310243
- Testing
- Palbociclib
- Where
- 24 sites in Germany
- Volunteers
- 50 people
- Sponsor
- University of Ulm
Leukemia
Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating children who have relapsed acute…
- Trial name
- NCT00003735
- Testing
- topotecan hydrochloride
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 11 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia (AML)
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children.
- Trial name
- NCT06679582
- Testing
- Luveltamab tazevibulin
- Where
- 36 sites in United States, Austria and 7 more
- Volunteers
- 1 people
- Sponsor
- Sutro Biopharma, Inc.
Leukemia
Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01139333
- Testing
- gene expression analysis, western blotting, flow cytometry
- Volunteers
- 52 people
- Sponsor
- Children's Oncology Group
NHL, Leukemia
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
This Trial is a FIH, open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with R/R B-cell NHL, CLL/SLL and AML who previously received standard…
- Trial name
- NCT04840784
- Testing
- ETH-155008
- Where
- 5 sites in Australia
- Volunteers
- 9 people
- Sponsor
- Shengke Pharmaceuticals Pty Ltd
Acute Myeloid Leukemia in Children
Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test
Acute myeloid leukemia (AML) accounts for about 15% to 20% of childhood leukemia, but the death rate accounts for about 50%. About 20-30% of children with AML did not achieve complete response (CR) after 2 induction treatments…
- Trial name
- NCT06233526
- Testing
- Chemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects…
- Trial name
- COSI (NCT04217278)
- Testing
- Vyxeos, Fludarabine, Busulphan
- Where
- 14 sites in United Kingdom
- Volunteers
- 333 people
- Sponsor
- University of Birmingham
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- AML-MDS 001 (NCT07270978)
- Testing
- CD33 FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT03674411
- Testing
- Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT04128748
- Testing
- Liposome-encapsulated Daunorubicin-Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
This study is aimed to evaluate the efficacy, safety, immunogenicity and pharmkinetics, pharmacodynamics of 6MW3211 as monotherapy and in combination with AZA or AZA plus VEN in patients with AML/MDS.
- Trial name
- NCT05448599
- Testing
- 6MW3211 injection with Intravenous Infusion
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Acute Myelogenous Leukemia
A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy
Prospective, nonrandomized, noncomparative, open-label, multicenter, 2-stage clinical study designed to determine the overall response (combined complete remission, complete remission with incomplete blood count recovery, partial…
- Trial name
- NCT00297921
- Testing
- tandutinib
- Sponsor
- Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myelodysplasia
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT
This study will evaluate a new maintenance therapy with the aim of improving the outcome of patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) after stem cell transplantation.
- Trial name
- AMADEUS (NCT04173533)
- Testing
- Oral azacitidine
- Where
- 20 sites in United Kingdom
- Volunteers
- 326 people
- Sponsor
- University of Birmingham
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT02220985
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
The study aim is to compare safety and efficacy of high-dose lenalidomide regimen, sequential azacitidine and lenalidomide and an azacitidine in persons ≥65 years with newly-diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT01358734
- Testing
- Azacitidine, Lenalidomide, Best Supportive Care (BSC)
- Where
- 30 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Celgene
Acute Myeloid Leukemia
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
A Clinical Study on the Safety and Effectiveness of targeting CD33 CAR-T Cell in the treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Trial name
- NCT06762132
- Testing
- CD33 CAR T-cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang University
Acute Myeloid Leukemia
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
This is a non-therapeutic study. Pediatric AML patients undergoing HCT with a myeloablative preparative regimen may be enrolled. Subjects can be enrolled 10-40 days prior to HCT.
- Trial name
- NCT01385787
- Where
- 38 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Leukemia, Myeloid Leukemia
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA.
- Conditions
- Leukemia, Myeloid Leukemia, Monocytic Leukemia
- Trial name
- NCT06429449
- Testing
- Venetoclax, Azacitidine, Mitoxantrone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Denver